Article Text
Abstract
Objective Serum creatinine is a byproduct of muscle metabolism, and low creatinine is postulated to be associated with diminished muscle mass. This study examined the association between low pre-operative serum creatinine and post-operative outcomes.
Methods This retrospective cohort study utilized the 2014–2021 National Surgical Quality Improvement Program to identify patients undergoing surgery with gynecologic oncologists. Patients with missing pre-operative creatinine, end-stage renal disease, sepsis, septic shock, dialysis, or pregnancy were excluded. Pre-operative creatinine was categorized into markedly low (≤0.44 mg/dL), mildly low (0.45–0.64 mg/dL), normal (0.65–0.84 mg/dL), and four categories of elevated levels (0.85–1.04, 1.05–1.24, 1.25–1.44, and ≥1.45 mg/dL). Outcomes included major (≥Grade 3) 30-day complications, categorized into any complications, wound, cardiovascular and pulmonary, renal, infectious, and thromboembolic complications. Also examined were 30-day readmissions, reoperations, and mortality. Logistic regressions assessed the association between creatinine and complications, with stratification by albumin and sensitivity analysis with propensity score matching.
Results Among 84 786 patients, 0.8% had markedly low, 19.6% mildly low, and 50.2% normal creatinine; the remainder had elevated creatinine. As creatinine decreased, the risks of major complications increased in a dose-dependent manner on univariable and multivariable analyses. A total of 9.6% (n=63) markedly low patients experienced major complications, second to creatinine ≥1.45 mg/dL (9.9%, n=141). On multivariable models, both markedly and mildly low creatinine were associated with higher odds of major complications (OR 1.715, 95% CI 1.299 to 2.264 and OR 1.093, 95% CI 1.001 to 1.193) and infections (OR 1.575, 95% CI 1.118 to 2.218 and OR 1.165, 95% CI 1.048 to 1.296) versus normal. Markedly low creatinine had similar ORs to creatinine ≥1.45 mg/dL and was further associated with higher odds of cardiovascular and pulmonary complications (OR 2.301, 95% CI 1.300 to 4.071), readmissions (OR 1.403, 95% CI 1.045 to 1.884), and mortality (OR 2.718, 95% CI 1.050 to 7.031). After albumin stratification, associations persisted for markedly low creatinine. Propensity-weighted analyses demonstrated congruent findings.
Conclusions Low creatinine levels are associated with major post-operative complications in gynecologic oncology in a dose-dependent manner. Low creatinine can offer useful information for pre-operative risk stratification, surgical counseling, and peri-operative management.
- Gynecologic Surgical Procedures
- Postoperative complications
- Surgery
- Surgical Procedures, Operative
Data availability statement
Data may be obtained from a third party and are not publicly available. Data were obtained from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database. These data are available to NSQIP-participating institutions.
Statistics from Altmetric.com
Data availability statement
Data may be obtained from a third party and are not publicly available. Data were obtained from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database. These data are available to NSQIP-participating institutions.
Footnotes
Contributors CCW: conceptualization, methodology, data curation, formal analysis, writing – original draft, guarantor. SB: writing – review and editing. OWF: writing – methodology, review and editing. ID: writing – review and editing. BV: writing – review and editing. MT: writing – methodology, review and editing. ELB: conceptualization, methodology, formal analysis, writing – review and editing.
Funding Thei study was funded by National Institute on Aging (NIA) (R03 AG074031-01).
Competing interests ELB received career development funds from the Gynecologic Oncology Group (GOG) Foundation and funds to the institution from the National Institute on Aging (NIA) (R03 AG074031-01).
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.